Every organ needs water to function properly. Even mild dehydration can lead to headaches, dry skin, dizziness, lower ...

Atrasentan shows clinically meaningful effects on kidney function in IgA nephropathy patients, including those receiving SGLT2 inhibitors.

In an interview, Jackson Peter Kim, MD, clinical assistant professor in the Division of Nephrology at Stanford Health Care, ...

While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes ...

A total of 340 biopsy-confirmed IgAN patients were randomised to daily oral Vanrafia or a placebo for approximately 132 weeks.

People with reduced kidney function may have higher levels of several blood markers commonly used in Alzheimer’s disease ...

Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Noninvasive ultrasound localization microscopy-based assessment of intrarenal microvasculature can reveal microvascular abnormalities at an early stage in individuals with polycystic kidney disease.

Biologically optimised plasma p-tau217 cutoffs improve amyloid beta detection accuracy and cost efficiency. Learn more about ...

Novartis announced that its investigational drug Vanrafia has successfully demonstrated the ability to slow kidney function decline in adults living with IgA nephropathy (IgAN), a chronic and ...

The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive ...